We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Poniard Announces Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
News

Poniard Announces Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

Poniard Announces Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
News

Poniard Announces Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Poniard Announces Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Poniard Pharmaceuticals, Inc. has announced the presentation of new efficacy and safety data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic castration-resistant prostate cancer (CRPC).

Results showed that the combination is active as first-line therapy for metastatic CRPC (also known as hormone-refractory prostate cancer) as demonstrated by prostate specific antigen (PSA) levels, time to PSA progression and radiologic response rates. Results also continue to show that picoplatin can be safely administered with full-doses of docetaxel and prednisone, the standard treatment for CRPC.

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla.

Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.
Advertisement